Gain Therapeutics Inc
NASDAQ:GANX

  • LAST PRICE
    2.3200
  • TODAY'S CHANGE (%)
    -0.1800 (-7.2000%)
  • Bid / Lots
    2.2700/ 10
  • Ask / Lots
    2.6300/ 6
  • Open / Previous Close
    2.5300 / 2.5000
  • Day Range
    2.3000
    2.5522
  • 52 Week Range
    0.8900
    5.3300
  • Volume
    351,319

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Oct 23, 2024

  • Oct 15, 2024

      Show headlines and story abstract

    • 7:00AM ET on Tuesday Oct 15, 2024 by Dow Jones
      Companies Mentioned: GANX

      Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

      BETHESDA, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a poster detailing the use of the Company's Magellan platform to discover novel allosteric discoidin domain receptor 2 (DDR2) inhibitors will be presented at the 36(th) EORTC-NCI-AACR (ENA) Symposium on molecular targets and cancer therapeutics being held October 23-25 in Barcelona, Spain. DDR2 displays aberrant expression and mutations across various cancer types and is involved in critical processes in tumor progression, including proliferation, migration, invasion, metastasis, epithelial-mesenchymal transition, and chemotherapy resistance. Allosteric small molecule inhibitors have the potential to overcome resistance and offer enhanced selectivity and safety compared to traditional kinase inhibitors.

  • Oct 9, 2024

  • Oct 7, 2024

      Show headlines and story abstract

    • 7:00AM ET on Monday Oct 07, 2024 by Dow Jones
      Companies Mentioned: GANX

      This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should, " or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with market conditions and the satisfaction of customary closing conditions related to the offering and uncertainties related to the offerings and the use of proceeds from the offerings. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company's business in general, please refer to the Company's prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company's Form 10-K for the year ended December 31, 2023 and Form 10-Q for the quarter ended June 30, 2024.

Peers Headlines